Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma
Authors:
- Leandro L. de MatosLMLeandro L. de Matos
- Gleice Margarete de S. ConceiçãoGCGleice Margarete de S. Conceição
- Antônio Carlos LopesALAntônio Carlos Lopes
- Helena B. NaderHNHelena B. Nader
- Maria Aparecida S. PinhalMPMaria Aparecida S. Pinhal
- 1 August 2008
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 20 (8) , 756-765
Abstract
Aim To propose a quantitative method to detect heparanase-2 (HPA2) and syndecan-1 (Syn-1) using immunohistochemistry in colorectal (colon and rectal) carcinomas compared with nonneoplastic tissues and evaluate the possible role of these molecules in tumor development and extracellular remodeling. Methods Cytoplasmic staining of HPA2 and Syn-1 was obtained by standard immunohistochemical reactions in 50 colorectal carcinoma and 20 nonneoplastic large bowels tissues. An image system was used to quantify the immunoexpression by digital computer-assisted method (Matos et al. 2006). The cutoff point for the immunohistochemistry variable was defined by sensibility and specificity curves. Statistical analysis was performed using SPSS version 13.0. Results HPA2 was over-expressed in colorectal cancer (131.1±24.9 o.u./μm2) when compared with nonneoplastic tissues (27.9±12.2 o.u./μm2) (P2) and (102.2±25.2 o.u./μm2) (P<0.0001). Conclusion A methodology with high sensitivity and specificity is proposed with a cutoff value for HPA2 and Syn-1 in the immunohistochemistry assay to define the presence of tumor. It was demonstrated for the first time in the literature that HPA2 is over-expressed in colorectal carcinoma tissues compared with nonneoplastic tissues. HPA2 over-expression could be possibly related to Syn-1 shedding despite the fact that HPA2 does not present enzymatic activity as HPA1.Keywords
This publication has 50 references indexed in Scilit:
- The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyBlood, 2007
- Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myelomaBlood, 2007
- FGF2 Binding, Signaling, Angiogenesis Are Modulated by Heparanase in Metastatic Melanoma CellsNeoplasia, 2006
- Epithelial Syndecan-1 Expression Is Associated with Stage and Grade in Colorectal CancerOncology, 2005
- Heparanase expression correlates with malignant potential in human colon cancerJournal of Cancer Research and Clinical Oncology, 2004
- Processing and activation of latent heparanase occurs in lysosomesJournal of Cell Science, 2004
- Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal developmentSeminars in Cancer Biology, 2002
- Cloning and Expression Profiling of Hpa2, a Novel Mammalian Heparanase Family MemberBiochemical and Biophysical Research Communications, 2000
- Syndecan family of cell surface proteoglycans: Developmentally regulated receptors for extracellular effector moleculesCellular and Molecular Life Sciences, 1995
- Cell recognition and adhesiveness: A possible biological role for the sulfated mucopolysaccharidesBiochemical and Biophysical Research Communications, 1977